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Summary
Background When cure is impossible, cancer treatment should focus on both length and quality of life. Maximisation 
of time without toxic eﬀ ects could be one eﬀ ective strategy to achieve both of these goals. The COIN trial assessed 
preplanned treatment holidays in advanced colorectal cancer to achieve this aim.
Methods COIN was a randomised controlled trial in patients with previously untreated advanced colorectal cancer. 
Patients received either continuous oxaliplatin and ﬂ uoropyrimidine combination (arm A), continuous chemotherapy 
plus cetuximab (arm B), or intermittent (arm C) chemotherapy. In arms A and B, treatment continued until 
development of progressive disease, cumulative toxic eﬀ ects, or the patient chose to stop. In arm C, patients who had 
not progressed at their 12-week scan started a chemotherapy-free interval until evidence of disease progression, when 
the same treatment was restarted. Randomisation was done centrally (via telephone) by the MRC Clinical Trials Unit 
using minimisation. Treatment allocation was not masked. The comparison of arms A and B is described in a 
companion paper. Here, we compare arms A and C, with the primary objective of establishing whether overall survival 
on intermittent therapy was non-inferior to that on continuous therapy, with a predeﬁ ned non-inferiority boundary 
of 1·162. Intention-to-treat (ITT) and per-protocol analyses were done. This trial is registered, ISRCTN27286448.
Findings 1630 patients were randomly assigned to treatment groups (815 to continuous and 815 to intermittent therapy). 
Median survival in the ITT population (n=815 in both groups) was 15·8 months (IQR 9·4–26·1) in arm A and 
14·4 months (8·0–24·7) in arm C (hazard ratio [HR] 1·084, 80% CI 1·008–1·165). In the per-protocol population 
(arm A, n=467; arm C, n=511), median survival was 19·6 months (13·0–28·1) in arm A and 18·0 months (12·1–29·3) 
in arm C (HR 1·087, 0·986–1·198). The upper limits of CIs for HRs in both analyses were greater than the predeﬁ ned 
non-inferiority boundary. Preplanned subgroup analyses in the per-protocol population showed that a raised baseline 
platelet count, deﬁ ned as 400 000 per μL or higher (271 [28%] of 978 patients), was associated with poor survival with 
intermittent chemotherapy: the HR for comparison of arm C and arm A in patients with a normal platelet count 
was 0·96 (95% CI 0·80–1·15, p=0·66), versus 1·54 (1·17–2·03, p=0·0018) in patients with a raised platelet count 
(p=0·0027 for interaction). In the per-protocol population, more patients on continuous than on intermittent treatment 
had grade 3 or worse haematological toxic eﬀ ects (72 [15%] vs 60 [12%]), whereas nausea and vomiting were more 
common on intermittent treatment (11 [2%] vs 43 [8%]). Grade 3 or worse peripheral neuropathy (126 [27%] vs 25 [5%]) 
and hand –foot syndrome (21 [4%] vs 15 [3%]) were more frequent on continuous than on intermittent treatment.
Interpretation Although this trial did not show non-inferiority of intermittent compared with continuous chemotherapy 
for advanced colorectal cancer in terms of overall survival, chemotherapy-free intervals remain a treatment option for 
some patients with advanced colorectal cancer, oﬀ ering reduced time on chemotherapy, reduced cumulative toxic eﬀ ects, 
and improved quality of life. Subgroup analyses suggest that patients with normal baseline platelet counts could gain the 
beneﬁ ts of intermittent chemotherapy without detriment in survival, whereas those with raised baseline platelet counts 
have impaired survival and quality of life with intermittent chemotherapy and should not receive a treatment break.
Funding Cancer Research UK. 
Introduction
The treatment of advanced colorectal cancer has improved 
substantially during the past decade with the introduction 
of new and more eﬀ ective drugs and advances in our 
understanding of the disease’s molecular biology. For 
many patients, these developments have changed the 
therapeutic perspective of advanced colorectal cancer from 
an acute to a chronic condition. Despite increasing use of 
surgery for metastatic disease, treatment remains palliative 
in intent for most patients. Therefore, from diagnosis 
onwards, an individual might spend most of their 
remaining life continuously on therapy, with the associated 
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toxic eﬀ ects, clinic attendances, detriment to quality of life, 
and expense. Strategies that minimise time on treatment, 
reduce side-eﬀ ects, and improve quality of life, while 
maintaining duration of survival, are highly desirable.
Before the introduction of irinotecan and oxaliplatin 
into treatment schedules for advanced colorectal cancer, 
ﬂ uorouracil-based chemotherapy was generally continued 
until unacceptable toxic eﬀ ects or disease progression. 
This approach has continued, with few trials examining 
alternative strategies. Most ongoing study protocols for 
ﬁ rst-line treatment of advanced colorectal cancer require 
a minimum of 6 months of continuous therapy for both 
standard and experimental arms. The resultant 
cumulative sensory neuropathy with oxaliplatin and 
hand–foot syndrome with ﬂ uoropyrimidines1 adversely 
aﬀ ect quality of life and overall dose intensity because of 
reduced dosing in subsequent treatment cycles.
One potential method to reduce toxic eﬀ ects and 
improve quality of life is to consider alternatives to 
continuous chemotherapy. Intermittent therapy given for 
a restricted period and then restarted, either after a 
predeﬁ ned interval (predeﬁ ned treatment) or at disease 
progression (repeat therapy), are such alternatives. 
Concerns remain that intermittent therapy in cancer 
could reduce tumour control or promote resistance to 
treatment. However, in breast and prostate cancer, 
intermittent hormones or cytotoxic agents have not 
reduced median overall survival.2–4
A previous Medical Research Council (MRC) trial, 
CR06B, assessed 354 patients with advanced colorectal 
cancer treated with the de Gramont (ﬂ uorouracil and 
folinic acid) schedule, continuous infusional ﬂ uorouracil, 
or raltitrexed.5 Those with stable or responding disease 
at 12 weeks were further randomly assigned to continue 
therapy until progressive disease or to stop, with the 
option to restart the same chemotherapy at later 
progression. There was no evidence of a diﬀ erence in 
overall survival between the two strategies (hazard ratio 
[HR] 0·87, 95% CI 0·69–1·09, p=0·23), with the results 
even slightly favouring intermittent over continuous 
treatment. Patients on intermittent chemotherapy had 
signiﬁ cantly fewer toxic eﬀ ects and serious adverse 
events than did those on continuous chemotherapy. 
Although criticised for its small size and failure of 
randomly assigned patients to restart protocol treatment, 
this trial gave impetus to the notion of intermit tent 
therapy in advanced colorectal cancer and set a precedent 
for further trials of intermittent combination 
chemotherapy.6
With its cumulative sensory neuropathy, oxaliplatin is 
an appropriate drug to use in the exploration of 
intermittent therapy and has been assessed in two trials, 
OPTIMOX-17 and OPTIMOX-2.8 In OPTIMOX-1,7 
continuous oxaliplatin and ﬂ uorouracil were compared 
with a novel strategy of planned oxaliplatin breaks, but 
with continuous ﬂ uorouracil. In OPTIMOX-2,8 the 
OPTIMOX-1 intermittent oxaliplatin strategy was 
compared with a complete chemotherapy-free interval 
strategy. Neither trial showed a signiﬁ cant reduction in 
survival with intermittent therapy, although OPTIMOX-2 
showed a trend in favour of continuation of ﬂ uorouracil 
during oxaliplatin breaks, and has been adopted as the 
benchmark for standard practice. This outcome is despite 
failure to recruit beyond phase 2 after the licensing of 
bevacizumab and that the trend in favour of continuous 
treatment was not statistically signiﬁ cant.
The phase 3 COIN trial (COntinuous or INtermittent) 
was developed to conclusively address this issue. We 
report here the results of this trial, to our knowledge 
the largest trial of intermittent versus continuous 
Figure 1: Trial design
Advanced colorectal cancer
Fit for chemotherapy
Measurable disease
No previous EGFR immunohistochemistry
Arm A (n=815)
Continuous chemotherapy until progression, toxicity, or patient choice
Fluorouracil or capecitabine
Oxaliplatin
Arm B (n=815)
Continuous chemotherapy plus cetuximab until progression, toxicity, or patient choice
Fluorouracil or capecitabine
Oxaliplatin
Cetuximab
Arm C (n=815)
Intermittent chemotherapy: treat for 12 weeks then stop and monitor; restart on progression for a 
further 12 weeks 
Fluorouracil or capecitabine
Oxaliplatin
Fluorouracil or capecitabine
Oxaliplatin
Fluorouracil or capecitabine
Oxaliplatin
Second-line therapy
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combination chemo therapy in ad vanced colorectal 
cancer. The COIN trial also assessed the eﬀ ect of addition 
of cetuximab to continuous oxaliplatin and ﬂ uoro pyrimi-
dine combination chemo therapy; the results of this 
comparison are reported in a companion paper.9
Methods
Study design and participants
The full protocol can be found on the MRC Clinical Trials 
Unit website. Patients were recruited by consultant 
oncologists at sites in the UK and Ireland that routinely 
undertake treatment of advanced colorectal cancer. 
Eligibility included written informed consent, age of at 
least 18 years, and histologically conﬁ rmed adeno-
carcinoma of the colorectum, inoperable metastatic or 
locoregional measurable disease (Response Evaluation 
Criteria In Solid Tumors [RECIST] version 1.0),10 no 
previous chemotherapy for metastatic disease, WHO 
per formance status 0–2, and good end-organ function. 
Patients were excluded if they had previous or present 
malignant disease, uncontrolled medical comorbidity 
likely to interfere with COIN treatment or response 
assessment, known brain metastases, or previous 
oxaliplatin exposure.
COIN was approved by the UK Medicines and Healthcare 
Regulatory Agency in June, 2004, and southwest 
multicentre research ethics committee in December, 2004. 
Approvals for the Irish sites were obtained from the Irish 
Medicines Board in November, 2006, and St James’s 
Hospital/Adelaide & Meath Hospital, Incorporating the 
National Children’s Hospital research ethics committee in 
December, 2006. The trial was coordinated by the MRC 
Clinical Trials Unit following the principles of International 
Conference on Harmonisation Good Clinical Practice 
guidelines, undertaken with a trial management group, 
monitored at regular intervals by an independent data 
monitoring committee, and overseen by an independent 
trial steering committee.
Randomisation and masking
Central telephone randomisation was done by the MRC 
Clinical Trials Unit, using the method of minimisa-
tion with a random element. The minimisation factors 
were hospital, WHO performance status, chemo-
therapy regimen, previous adjuvant chemotherapy, 
liver metastases, and peritoneal metastases. Patients 
were randomly assigned (1:1:1) to the control arm 
of continuous oxaliplatin-based (oxaliplatin plus 
capecitabine or oxaliplatin plus ﬂ uorouracil and folinic 
acid) chemotherapy (arm A) or one of two research arms: 
continuous chemotherapy plus cetuximab (arm B) or 
intermittent chemotherapy (arm C; ﬁ gure 1). Treatment 
allocation was not masked.
Procedures
Oncologists chose between the two chemotherapy 
regimens according to local hospital policy or patient 
preference. Oxaliplatin plus capecitabine was given as a 
3-weekly regimen of intravenous oxaliplatin 130 mg/m² 
over 2 h followed by oral capecitabine 1000 mg/m² twice a 
day for 2 weeks. Oxaliplatin plus ﬂ uorouracil and folinic 
acid was given as a 2-weekly regimen of intravenous 
L-folinic acid 175 mg or D,L-folinic acid 350 mg over 2 h 
given concurrently with oxaliplatin 85 mg/m² over 2 h, 
followed by intravenous bolus ﬂ uorouracil 400 mg/m², 
and ﬁ nally ﬂ uorouracil 2400 mg/m² infusion over 46 h 
via an ambulatory pump.
In arm A, treatment was continued until RECIST-
deﬁ ned progressive disease, development of cumulative 
toxic eﬀ ects (precluding both oxaliplatin and ﬂ uoro-
pyrimidine use), or patients chose to stop. Patients on 
arm C received chemotherapy for 12 weeks, after which 
treatment was stopped completely and the patients 
Arm A (N=815) Arm C (N=815)
Choice of chemotherapy at baseline
Capecitabine-based 536 (66%) 533 (65%)
Fluorouracil-based 279 (34%) 282 (35%)
Sex
Male 525 (64%) 523 (64%)
Female 290 (36%) 292 (36%)
Age
Median (years) 63 (56–69) 63 (58–70)
≥75 years 74 (9%) 69 (8%)
WHO performance status
0 375 (46%) 375 (46%)
1 378 (46%) 378 (46%)
2 62 (8%) 62 (8%)
Previous adjuvant chemotherapy
None 608 (75%) 608 (75%)
1–6 months 36 (4%) 36 (4%)
>6 months 128 (16%) 131 (16%)
Yes (unspeciﬁ ed) 43 (5%) 40 (5%)
Site of primary tumour
Rectum 243 (30%) 252 (31%)
Status of primary tumour
Resected 445 (55%) 419 (51%)
Unresected 331 (41%) 350 (43%)
Local recurrence 39 (5%) 46 (6%)
Metastases
Metachronous 249 (31%) 241 (30%)
Synchronous 552 (68%) 567 (70%)
Liver only 174 (21%) 179 (22%)
Liver and others 436 (53%) 430 (53%)
Non-liver 198 (24%) 200 (25%)
Number of metastatic sites
One 283 (35%) 284 (35%)
Two 326 (40%) 329 (40%)
More than two 199 (24%) 196 (24%)
Data are n (%) or median (IQR).
Table 1: Baseline characteristics
For the COIN trial protocol see 
http://www.ctu.mrc.ac.uk/
plugins/StudyDisplay/protocols/
COIN%20Protocol%20v5.1%20
October%202009.pdf
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were assessed. Patients with progressive disease came 
oﬀ  protocol treatment and those with stable or 
responding disease began a complete chemotherapy-
free interval. Because the primary endpoint was overall 
survival, responses were not conﬁ rmed by repeat scans 
and external radiological review was not undertaken. 
During their chemotherapy-free interval, patients were 
assessed clinically at least every 6 weeks and 
radiologically every 12 weeks (or sooner if clinically 
indicated). The intermittent strategy was that the same 
chemotherapy was to be restarted on conﬁ rmation of 
progressive disease (with this scan becoming the new 
baseline measure ment). Repeated chemotherapy cycles 
and chemotherapy-free intervals were continued until 
progressive disease on treatment was documented or 
patients chose to stop protocol therapy. Detailed dose 
reduction and delay protocols were provided 
(see protocol).
Patient symptoms were assessed by investigators 
throughout treatment and scored with National Cancer 
Institute Common Toxicity Criteria for Adverse Events 
(version 3.0).11 Serious adverse events and deaths, together 
with an assessment of causality, were continuously 
reported and these were further assessed by an expert 
practising oncologist on behalf of the MRC.
Patients completed the European Organisation for 
Research and Treatment of Cancer quality-of-life core 
questionnaire (QLQ-C30)12 and ﬁ ve additional questions 
(with similar structure to that used in the QLQ-C30) 
about trial-speciﬁ c symptoms and patient views on how 
acceptable and worthwhile their treatment was. Forms 
were scheduled to be completed at baseline (before 
randomisation), 6 weeks, 12 weeks, and every 12 weeks 
thereafter (before knowledge of CT scan results).
The primary objective of this part of the COIN trial was 
to establish whether intermittent therapy was non-
inferior to continuous therapy in terms of overall survival 
in patients with advanced colorectal cancer. The secondary 
aims were to evaluate failure-free survival (of the 
treatment strategies), response, toxic eﬀ ects, quality of 
life, and cost-eﬀ ectiveness. Results of the cost-
eﬀ ectiveness analysis are not yet available. The primary 
quality-of-life outcome measures were palliation, toxic 
eﬀ ects, functional scales, and global quality of life.
Statistical analysis
The sample size for comparison of arm A versus C was 
1614 patients (807 per arm). In the UK-based FOCUS trial,1 
patients receiving continuous chemotherapy had 2-year 
overall survival of 20% and a median overall survival of 
Figure 2: Trial proﬁ le
PP=per-protocol. *Protocol violation refers to the speciﬁ c violation of either continuing therapy if in arm C or of stopping therapy if in arm A.
815 randomised to arm A 815 randomised to arm C
2445 patients enrolled
303 exclusions in the ﬁrst 12 weeks  
           69 deaths
         104 progressive disease
           60 came oﬀ trial for other speciﬁc reason
            21 too few treatment cycles
           49 no valid 12-week assessment
512 had valid 12-week assessment:
        result not progressive disease
525 had valid 12-week assessment:
        result not progressive disease
    45 excluded
            2 one further cycle but only to 
complete original 12-week period 
            1 lost to follow-up
          13 protocol violation*
          29 came oﬀ trial for other speciﬁc reason
                 within 35–42 days of 12-week 
                 assessment
               6 planned surgery
               7 second-line therapy
               3 clinician decision (other than 
                     second-line)
               3 progression
               4 toxic eﬀects
               3 intercurrent illness
               3 patient decision
    14 excluded
      1 lost to follow-up
     6 protocol violation*
      7 came oﬀ trial for other speciﬁc reason
          within 35–42 days of 12-week 
          assessment
          2 planned surgery
          2 second-line therapy
          2 clinician decision (other than 
              second-line)
          1 other (patient had bowel 
obstruction and needed a stent)
815 randomised to arm B
A vs B comparison is reported in 
reference 9
290 exclusions in the ﬁrst 12 weeks  
           63 deaths
         106 progressive disease
           68 came oﬀ trial for other speciﬁc reason
            17 too few treatment cycles
           36 no valid 12-week assessment
467 PP analysis population 511 PP analysis population
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15·4 months. To show non-inferiority with a one-sided 
log-rank test with α of 0·1 and power of 90%, 1420 patients 
would be needed (710 patients per arm). This size would 
reliably exclude a diﬀ erence worse than 4·6% in 2-year 
survival (or >2·15 months in median overall survival). The 
predeﬁ ned non-inferiority boundary was 1·162. To account 
for the roughly 12% of patients who progress or who do 
not complete 12 weeks of treatment and therefore would 
not contribute to the comparison, the target sample size 
was increased to 807 patients per arm, and the analysis 
was timed to be done when at least 1168 overall survival 
events had occurred. The primary analysis was one-sided 
at 90% signiﬁ cance, with the conﬁ dence limit calculated 
as the upper limit of a two-sided 80% CI. All other analyses 
were two-sided at a 95% signiﬁ cance level. Stata 
(version 11.1) was used for all statistical analyses.
The primary question was one of non-inferiority, so 
both intention-to-treat (ITT) and per-protocol analyses 
of overall survival were planned. The ITT analysis 
included all patients randomly allocated to treatment 
groups, whereas the per-protocol analysis included 
patients who reached the point at which continuous 
and intermittent strategies diverged—ie, they received 
a full 12 weeks’ treatment (allowing for one missed 
cycle), remained on trial, and had no evidence of 
progressive disease at 12 weeks (within 4 weeks). 
Additionally, the patients included in the per-protocol 
analysis had to have adhered to the assigned protocol 
strategy at 12 weeks—ie, patients in arm A continuing 
treatment and those in arm C starting a chemotherapy-
free interval. This population was deﬁ ned to correspond 
to the patient cohort who, when seen at the 12-week 
timepoint (outside a trial context), would beneﬁ t 
from discussion about whether to continue treatment 
or begin a chemotherapy-free interval. 
Overall survival was calculated as time from 
randomisation to death from any cause. At the time of 
analysis, survivors were censored at the date that they 
were last known to be alive. Strategy-failure-free survival 
was deﬁ ned as the time from randomisation to failure 
Figure 3: Kaplan-Meier curves for overall survival in (A) the ITT population and (B) the per-protocol population, and strategy-failure-free survival in (C) the 
ITT population and (D) the per-protocol population
Median survival in each arm is derived directly from the Kaplan-Meier curve. Additionally, for overall survival we present median survival in arm C corresponding to the 
one-sided 90% (ie, upper 80%) conﬁ dence limit (CL) of the hazard ratio (HR); and for comparison, the limit of median survival regarded non-inferior with the pre deﬁ ned 
non-inferiority bound of HR 1·162. This is intended to give a clinical interpretation of the results as compared with the prespeciﬁ ed bound. ITT=intention-to-treat.
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Articles
www.thelancet.com/oncology   Vol 12   July 2011 647
of the COIN strategy to which a patient was randomly 
assigned (webappendix p 3). In the continuous treatment 
group, this measure equated to conventional 
progression-free survival. In the intermittent treatment 
group, a strategy-failure-free survival event occurred 
when a patient had progressive disease during a planned 
treatment period or within 8 weeks of starting a 
chemotherapy-free interval. Patients were censored at 
the last date for which a case report form was completed. 
The primary analysis timepoint for quality of life was 
24 weeks after randomisation, but baseline and 12-week 
data were also analysed since these timepoints were 
milestones in the treatment strategy. Only patients in 
the per-protocol population with data at all three 
timepoints were analysed. Ordinal logistic regression 
was used to predict 12-week and 24-week scores rounded 
into ﬁ ve categories, adjusting for treatment arm and 
previous scores.
We compared rates of toxic eﬀ ects between treatment 
groups using a χ² test, or Fisher’s exact test in case of low 
event rates (n<5). Prognostic and predictive modelling 
was done with Cox proportional hazards regression. To 
investigate the eﬀ ect of prespeciﬁ ed covariates on 
survival, we built prognostic models using a backward 
stepwise approach with critical value p=0·05 for both 
removal from and re-entry into the model at each 
iteration. To investigate whether these covariates modiﬁ ed 
the treatment eﬀ ect, predictive models were ﬁ tted that 
included the covariate, treatment arm, and a treatment-
predictive factor interaction term; interaction tests were 
done with likelihood-ratio tests of the null hypothesis 
that the interaction coeﬃ  cient is zero.
This trial is registered, ISRCTN27286448.
Role of the funding source
The trial was conceived and developed by the National 
Cancer Research Institute advanced colorectal clinical 
studies group. The MRC was the overall sponsor of the 
study, with some responsibilities for the sites in Ireland 
delegated to the Irish Clinical Oncology Research 
Group. The MRC Clinical Trials Unit was responsible 
for all data collection and analysis, and contributed to 
the writing of the report. The corresponding author had 
full access to the data and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Between March 9, 2005, and May 9, 2008, 2445 patients 
were randomly allocated to treatment groups at 111 centres 
in the UK and Ireland, with 1630 patients assigned to the 
comparison of continuous versus intermittent treatment. 
Table 1 shows their baseline characteristics, which were 
well balanced between the trial arms. Figure 2 shows the 
progress of patients through the stages of the trial. At the 
time of analysis (database locked Sept 2, 2009), the 
median duration of follow-up among surviving patients 
assigned to arm A was 20·9 months (IQR 16·1–28·3) 
and to arm C was 21·8 months (16·2–29·5). 28 (7%) of 
383 surviving patients had no data returned for 12 months 
and were deemed lost to follow-up.
35 (2%) patients did not start trial therapy because of 
clinical deterioration after randomisation, patient 
choice, or subsequent ineligibility after randomisation. 
Two-thirds of all patients randomly assigned to treatment 
groups (536 in arm A, 533 in arm C) received 
capecitabine-based chemotherapy, and 34% (279 in 
arm A, 282 in arm C) received ﬂ uorouracil-based 
Arm A Arm C
12 weeks 
(N=815)
Best overall 
(N=815)
12 weeks 
(N=815)
Best overall 
(N=815)
Best after 
rechallenge 
(N=325)
Complete response 18 (2%) 40 (5%) 13 (2%) 22 (3%) 0 
Partial response 339 (42%) 377 (46%) 365 (45%) 399 (49%) 88 (27%)
Stable disease* 198 (24%) 184 (23%) 196 (24%) 200 (25%) 103 (32%)
Progressive disease 96 (12%) 113 (14%) 96 (12%) 112 (14%) 77 (24%)
Missing 12 (1%) 0 9 (1%) 0 11 (3%)
Not assessed 152 (19%) 101 (12%) 136 (17%) 82 (10%) 46 (14%)
Data are n (%). *In the COIN dataset, the ﬁ rst disease response assessment was at around 12 weeks; therefore, patients 
with stable disease must have (at least) maintained this stability for that length of time. 
Table 2: Response at 12 weeks and best response in arms A and C and response after rechallenge (arm C only)
12 weeks 24 weeks
OR (95% CI) p value OR (95% CI) p value
Functional scales
Impaired physical functioning 1·13 (0·97–1·30) 0·11 0·99 (0·83–1·18) 0·89
Impaired role functioning 1·11 (0·97–1·27) 0·13 0·82 (0·70–0·96) 0·015
Impaired emotional functioning 1·14 (0·98–1·31) 0·086 1·01 (0·85–1·20) 0·90
Impaired cognitive functioning 1·07 (0·92–1·23) 0·37 0·90 (0·76–1·07) 0·24
Impaired social functioning 1·05 (0·91–1·20) 0·52 0·82 (0·70–0·96) 0·016
Symptom scales
Fatigue 1·02 (0·89–1·17) 0·75 0·73 (0·62–0·87) 0·00025
Nausea or vomiting 1·03 (0·90–1·19) 0·65 0·82 (0·68–0·98) 0·033
Pain 1·03 (0·89–1·20) 0·66 1·38 (1·16–1·64) 0·00029
Dyspnoea 1·06 (0·92–1·23) 0·40 1·00 (0·84–1·20) 0·99
Insomnia 1·10 (0·95–1·26) 0·19 0·94 (0·79–1·11) 0·44
Appetite loss 1·08 (0·94–1·25) 0·28 0·80 (0·67–0·95) 0·012
Constipation 1·09 (0·93–1·28) 0·28 0·82 (0·68–0·99) 0·037
Diarrhoea 0·98 (0·85–1·13) 0·79 0·79 (0·66–0·94) 0·008
Dry or sore mouth 1·04 (0·90–1·19) 0·62 0·66 (0·55–0·79) <0·0001
Problems eating or drinking 1·23 (1·00–1·50) 0·045 0·63 (0·47–0·84) 0·0021
Problems handling small objects 1·12 (0·96–1·32) 0·16 0·54 (0·45–0·65) <0·0001
Treatment interferes with daily activities 1·01 (0·89–1·16) 0·83 0·62 (0·52–0·73) <0·0001
Treatment felt to have been worthwhile 0·94 (0·80–1·11) 0·46 1·20 (0·96–1·50) 0·12
Global scales
Global quality of life 1·08 (0·93–1·25) 0·30 0·98 (0·83–1·15) 0·81
Odds ratios (ORs) are for arm C compared with arm A, and are from ordinal regression models adjusting for previous 
timepoints (baseline, 12 weeks). ORs greater than 1 indicate worse quality of life, and ORs less than 1 indicate better 
quality of life.
Table 3: Quality of life at 12 and 24 weeks
See Online for webappendix
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therapy. No major diﬀ erences were identiﬁ ed by choice 
of chemotherapy for any of the outcome measures of 
this comparison. In the per-protocol population, the 
geometric mean overall time on treatment in arm C was 
5·2 months (95% CI 5·0–5·4) versus 7·5 months 
(7·3–7·8) in arm A (p<0·0001). Although total dose 
delivered of chemo therapeutic agents was greater in 
arm A than in arm C (p<0·0001), dose intensity was 
greater in arm C during on-treatment periods 
(p<0·0001). In the intermittent treatment group, 
325 (64%) of 511 potentially eligible patients restarted a 
second 12-week course of chemo therapy after a 
chemotherapy-free interval.
1247 (77%) deaths had occurred in the ITT population 
at the time of analysis. Median survival in the ITT 
population was 15·8 months (IQR 9·4–26·1) in arm A 
and 14·4 months (8·0–24·7) in arm C, and in the per-
protocol population was 19·6 months (13·0–28·1) in 
arm A and 18·0 months (12·1–29·3) in arm C. The HR 
point estimates were 1·084 (80% CI 1·008–1·165) in the 
ITT population and 1·087 (0·986–1·198) in the per-
protocol population; the upper limits were higher than 
the predeﬁ ned non-inferiority boundary (ﬁ gure 3). 
Kaplan-Meier overall survival in the ITT population for 
arm A versus arm C was 28·7% versus 26·5% at 2 years 
and 13·0% versus 11·2% at 3 years.
1166 (94%) of 1247 deaths in the ITT population were 
due to colorectal cancer. 22 (2%) deaths were reported to 
be treatment-related, 52 (4%) were from other causes, 
and the cause of death for the remaining seven (<1%) is 
currently unknown. 70 (6%) deaths occurred within 
60 days of randomisation, with no diﬀ erence between 
the two groups.
Median strategy-failure-free survival in the ITT 
population was 8·4 months (IQR 5·3–11·8) in arm A 
and 7·4 months (5·1–12·1) in arm C, and in the per-
protocol population was 9·2 months (7·0–12·9) in 
arm A and 8·7 months (5·9–13·4) in arm C. From the 
Kaplan-Meier plots (ﬁ gure 3), intermittent therapy 
seemed to result in a greater loss of patients (in terms of 
strategy) early on, especially around 6–9 months, but at 
2 years there was little diﬀ erence in number of patients 
remaining on strategy: 2-year survival in the ITT analysis 
was 7·4% (n=28) in the continuous treatment arm and 
7·6% (n=35) in the intermittent treatment arm, and in 
the per-protocol analysis was 7·7% on continuous (n=18) 
and 7·6% on intermittent (n=24) treatment.
Among patients in the per-protocol population allocated 
intermittent treatment who commenced a chemotherapy-
free interval (n=511), the median time to progression was 
12·9 weeks (3·0 months; IQR 10·9–24·0 weeks). Among 
those who later restarted trial therapy (n=325), the 
median overall length of the chemotherapy-free interval 
before progression was 16·0 weeks (3·7 months; 
IQR 13·7–26·0 weeks). The median number of 
chemotherapy-free intervals was two (range one to six).
Protocol treatment in both treatment groups was 
identical up to 12 weeks (the time of the ﬁ rst scheduled 
radiological disease assessment). 192 (12%) patients in 
the ITT population had progressive disease at 12 weeks 
(table 2). Best overall response (by RECIST criteria) did 
not diﬀ er between treatment groups, suggesting that 
most patients achieve best response within the ﬁ rst 
12 weeks of therapy. Among the 268 patients allocated 
intermittent treatment who restarted a second 12-week 
course of chemotherapy after a chemotherapy-free 
Figure 4: Eﬀ ects of adherence to protocol on overall survival within the per-protocol population
Interaction with treatment arm: hazard ratio (HR) 1·08 (95% CI 0·80–1·46); p=0·60.
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interval and had a second response assessment 12 weeks 
later, 87 (32%) had a partial response, 101 (38%) had 
stable disease, and 80 (30%) had progressive disease.
Haematological toxic eﬀ ects and hand –foot syndrome 
were more common on continuous treatment than on 
intermittent treatment, whereas nausea and vomiting 
occurred more often in patients receiving intermittent 
treatment. Grade 3 or worse peripheral neuropathy and 
hand –foot syndrome were more frequent during 
continuous treatment (webappendix p 4).
There were fewer eligible patients in arm C (79%, 
n=647) than in arm A (89%, n=724; p<0·0001), since 
more patients in arm C either remained on trial therapy 
(6% vs 1% in arm A, n=46 vs nine, p<0·0001) or died (14% 
vs 9% in arm A, n=115 vs 74, p=0·0015). Among patients 
judged eligible to receive second-line therapy, this 
treatment was given to signiﬁ cantly fewer patients on 
intermittent therapy (52%, n=336) than on continuous 
therapy (62%, n=448; p=0·00020).
Quality of life in the per-protocol population at baseline, 
12 weeks, and 24 weeks was assessable in 279 (60%) 
patients on continuous treatment and 282 (55%) patients 
on intermittent treatment. Less than two-thirds of 
patients complied with the quality-of-life component of 
COIN. No clear evidence of diﬀ erences in baseline 
characteristics was identiﬁ ed between those patients who 
completed quality-of-life questionnaires and all patients 
randomly allocated to treatment groups, but the risk of 
such diﬀ erences cannot be eliminated. After adjustment 
for previous measurements, there were signiﬁ cant 
beneﬁ ts from intermittent therapy at 24 weeks for fatigue, 
dry or sore mouth, problems eating and drinking, 
diﬃ  culty handling small objects, interference with daily 
activities, nausea or vomiting, appetite loss, constipation, 
and diarrhoea (table 3; p<0·05 for all). Intermittent 
therapy also had beneﬁ ts in terms of role functioning 
(p=0·015) and social functioning (p=0·016; table 3). By 
contrast, the only signiﬁ cant factor suggesting detriment 
from intermittent therapy was the symptom scale of pain 
(p=0·00029; table 3). At 12 weeks, there was a non-
signiﬁ cant trend towards an adverse eﬀ ect of intermittent 
therapy on emotional functioning (p=0·086), but this 
result was not evident at 24 weeks (p=0·90; table 3).
We undertook a post-hoc exploratory analysis of the 
eﬀ ects of protocol adherence on overall survival. Clinicians 
were classiﬁ ed according to the proportion of their patients 
assigned to intermittent therapy in the per-protocol 
population who restarted treatment after a chemotherapy-
free interval. A cutoﬀ  of 60% was chosen because this 
proportion formed a pragmatic and appropriate bench-
mark midway between the 40% and 80% of restarts 
reported in OPTIMOX-1 and OPTIMOX-2, respectively. 
For so-called adherent clinicians, there was no survival 
diﬀ erence between arms A and C. But for non-adherent 
clinicians, there was an early survival advantage for arm A. 
However, this diﬀ erence lessens over time and the overall 
HR is non-signiﬁ cant (ﬁ gure 4).
15 prespeciﬁ ed factors were entered into a prognostic 
model to predict overall survival in the per-protocol 
population, together with the post-hoc factor of restart 
adherence rate. The ﬁ nal model contained the following 
previously identiﬁ ed prognostic variables: previous 
adjuvant chemotherapy or surgery; alkaline phosphatase; 
body surface-area; platelet count; time from diagnosis to 
Figure 5: Subgroup analyses of overall survival within the per-protocol population
HR=hazard ratio. WBC=white blood cell. CEA=carcinoembryonic antigen.
All patients 978 1·09 (0·94–1·26)
Sex
   Male 657 1·10 (0·92–1·32)
   Female 321 1·05 (0·81–1·36)
Age
   ≤65 years 577 1·15 (0·95–1·40)
   >65 years 401 1·00 (0·80–1·27)
Site
   Right colon 243 1·20 (0·90–1·60)
   Left colon/rectum 727 1·06 (0·89–1·27)
Number of metastatic sites
   0–1 332 1·19 (0·91–1·54)
   ≥2 646 1·05 (0·88–1·26)
Primary tumour resected
   No 445 1·06 (0·86–1·31)
   Yes 533 1·07 (0·87–1·32)
Choice of chemotherapy
   Capecitabine-based 630 1·05 (0·87–1·27)
   Fluorouracil-based 348 1·13 (0·88–1·45)
Liver metastases only
   No 763 1·00 (0·85–1·19)
   Yes 215 1·43 (1·03–1·97)
Synchronous
   No 296 1·23 (0·93–1·63)
   Yes 676 1·03 (0·87–1·24)
WHO performance status
   0 920 1·10 (0·95–1·29)
   ≥1 58 0·99 (0·54–1·80)
WBC count
   <10 000 per μl 719 1·06 (0·89–1·27)
   ≥10 000 per μl 259 1·19 (0·90–1·58)
CEA
   <100 μg/L 432 0·94 (0·75–1·19)
   ≥100 μg/L 343 1·25 (0·99–1·58)
Alkaline phosphatase
   <300 U/L 836 1·08 (0·92–1·27)
   ≥300 U/L 142 1·21 (0·83–1·76)
Platelet count
   <400 000 per μl 703 0·96 (0·80–1·15)
   ≥400 000 per μl 271 1·54 (1·17–2·03)
KRAS status
   Wild-type 481 1·23 (0·99–1·54)
   Mutant 310 0·90 (0·70–1·16)
12-week disease status
   Response 653 1·17 (0·97–1·42)
   Stable disease 325 0·96 (0·75–1·23)
Restart compliance
   ≤60% 469 1·14 (0·92–1·41)
   >60% 509 1·05 (0·85–1·29)
 n  HR (95% CI) 
0·5 1 2
Favours intermittent therapy Favours continuous therapy
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randomisation; resection of primary tumour; mutation 
present in any of KRAS, NRAS, or BRAF; and number of 
metastatic sites. In particular, each of the four variables 
identiﬁ ed by Köhne and colleagues13 were present with 
the exception of white blood cell count (in our data, 
platelet count was a stronger prognostic indicator), and 
the score deﬁ ned by Köhne was strongly prognostic 
(p<0·0001 for trend). The 16 factors entered into the 
prognostic model were also explored for predictive value 
for overall survival in the per-protocol population 
(ﬁ gure 5). The strongest predictive factor, and the only 
one with an interaction signiﬁ cant at the 5% level, was 
platelet count. A raised platelet count at baseline 
(≥400 000 per μL, recorded for 271 [28%] of 978 patients) 
predicts a signiﬁ cant survival detriment from intermittent 
chemotherapy (p=0·0027 for interaction; ﬁ gure 6). Raised 
baseline platelet count had an even greater predictive 
eﬀ ect for a detriment from intermittent therapy on 
24-week quality of life, particularly for functional scales 
(p<0·05 for all), for which a consistent trend was noted 
towards beneﬁ t from intermittent therapy for patients 
with normal platelet count and an adverse eﬀ ect for 
patients with raised platelet count. Additionally, the 
symptom scales of fatigue, pain, dyspnoea, appetite loss, 
constipation, and global quality of life followed this trend 
(p<0·05 for all). Furthermore, patients on intermittent 
therapy were signiﬁ cantly more likely than were those on 
continuous therapy to report at 24 weeks that their 
treatment had not been worthwhile if their baseline 
platelet count was raised (p=0·048 for interaction; 
webappendix p 7). All these results were independent of 
known prognostic factors. Baseline platelet count and 
progression between 12 and 24 weeks were not associated 
in this dataset (p=0·41). Other factors with interactions 
signiﬁ cant at the 10% level were presence of metastases 
in the liver only (p=0·066) and tumoral KRAS status 
(p=0·070).
Discussion
The goal of palliative chemotherapy is to increase 
overall survival with improvement or minimum deﬁ cit 
in quality of life. This study provides a large dataset 
relevant to the eﬀ ect of chemotherapy-free intervals on 
both overall survival and quality of life in advanced 
colorectal cancer. The trial did not meet its primary 
outcome objective, which was to show non-inferiority 
of intermittent chemotherapy versus continuous 
chemotherapy as ﬁ rst-line therapy in advanced 
colorectal cancer. This policy therefore cannot be 
routinely recommended for all patients. However, there 
seems to be a large subpopula tion of patients for whom 
intermittent therapy provides similar survival beneﬁ t 
and can be recommended.
The COIN trial has shown that intermittent 
chemotherapy is associated with improved quality of life, 
shortened time on chemotherapy, reduced number of 
visits to hospital, and a minimum diﬀ erence in overall 
survival. Non-inferiority trials are often misconstrued as 
equivalence trials, which they are not. The outcomes of 
such trials give an indication of similarity, which should 
be interpreted with all relevant data in hand and not as a 
single endpoint. In COIN, we developed a statistical plan 
that set the outer bound of the HR for non-inferiority for 
overall survival at the rigorous level of 1·162 (for 
comparison, the outer bound in the comparison of 
ﬂ uorouracil versus capecitabine in the X-ACT trial 
was 1·25).14 The trial did not meet this strict criterion 
(upper limit of HR in the ITT group was 1·165). This 
Figure 6: Kaplan-Meier curves of overall survival within the per-protocol population, by baseline platelet subgroup
Interaction with treatment arm: hazard ratio (HR) 1·646 (95% CI 1·188–2·279); p=0·0027.
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result does not suggest that continuous chemotherapy is 
superior to an intermittent strategy, but does translate 
into an observed diﬀ erence in median overall survival of 
around 6 weeks (1·4 months), favouring continuous 
therapy. Our conﬁ dence intervals reliably exclude a 
detriment greater than 2·2 months (ITT analysis) or 
3·2 months (per-protocol analysis) in median overall 
survival with intermittent therapy.
The striking outcome from the study is the signiﬁ cant 
correlation of a raised baseline platelet count as a 
predictive biomarker for use of a continuous or 
intermittent chemotherapy strategy. We analysed a full 
range of prognostic factors including those in the Köhne 
prognostic index13 to assess correlation with outcome. A 
quarter of patients had a raised platelet count at baseline 
and these patients had substantially inferior survival (a 
5-month reduction in survival; test for interaction 
p=0·0027) when treated with intermittent chemotherapy 
and also impaired quality of life on almost all scales 
apart from those directly related to toxic eﬀ ects of 
chemotherapy. By contrast, the three-quarters of patients 
with normal platelet counts had improved quality of life 
on almost all measures, with no detriment in overall 
survival. Raised platelet count has previously been 
identiﬁ ed as a poor prognostic marker in advanced 
colorectal cancer.13 The mechanism could relate to 
paracrine feedback driven by cytokines including 
interleukin 6, directly causing throm bocytosis.15 It could, 
alternatively, relate to an aspect of immunomodulation 
driven by T-regulatory cells and FOXP3 epigenetic 
regulation.16 If conﬁ rmed in other datasets, the easily 
measurable marker of a raised platelet count at initiation 
of chemotherapy would be a helpful and cost-eﬀ ective 
predictive biomarker for identiﬁ cation of patients in 
whom continuous therapy might be preferable in order 
to maximise symptom control and survival.
The shorter overall survival in this UK trial compared 
with some other trial settings is probably related to a 
combination of several factors, such as a more advanced 
distribution of disease at presentation, fewer available 
eﬀ ective treatments, or diﬀ erent attitudes of patients 
and clinicians to additional therapy. A recent report17 
shows from registry data that survival for colorectal 
cancer is lower in the UK than for other comparable 
countries (for 1-year survival UK registries reported 75% 
compared with 80–85% for the other registries in the 
comparable years 2005–07; 54% vs 58–66% at 5 years). 
The patterns are consistent with later stage at diagnosis 
or diﬀ erences in treatment, particularly in Denmark and 
the UK. Since COIN recruited widely from 111 centres 
across the UK and Ireland and had broad inclusion 
criteria, it is likely to be representative of outcomes for 
advanced colorectal cancer in the UK.
Failure to restart oxaliplatin-based chemotherapy after 
an interval has previously been identiﬁ ed as detrimental 
to survival.18 In the COIN per-protocol population 
(ie, patients clinically eligible to recommence chemo-
therapy), 325 (64%) of 511 potentially eligible patients 
restarted a second 12-week course of chemo therapy. This 
proportion compares with a reintroduction rate of 40% in 
OPTIMOX-17 and 80% in OPTIMOX-2, which recruited 
patients from only 12 centres and in which high rates of 
reintroduction were protocol mandated.8 The ﬁ gure of 
64% from the COIN trial could reason ably represent a 
good reﬂ ection of real practice in an incurable disease, in 
which chemotherapy must strike a balance between 
quality and length of life. The proportion of COIN 
patients restarting oxaliplatin and the low numbers 
receiving second-line chemotherapy regimens compared 
with some other countries reﬂ ects a less aggressive 
approach that is characteristic of UK oncology and could 
also have contributed to the lower overall survival.
Additionally, the predominantly UK study setting is 
important in that bevacizumab was not reimbursed for 
ﬁ rst-line treatment or subsequent use in routine NHS 
practice during the study period, and although its 
availability would probably have resulted in longer 
overall survival, the eﬀ ect of addition of this targeted 
agent on a chemotherapy-free interval strategy is 
unclear. Three randomised trials are examining this 
issue,19–21 but preliminary data are only available for 
one. The TTD MACRO trial19 assessing continuous 
oxaliplatin, capecitabine, and bevacizumab versus 
intermittent chemotherapy with maintenance 
bevacizumab demonstrated non-inferiority by their 
criteria in terms of median time to ﬁ rst progression 
of 11·0 versus 10·3 months (HR 1·07, 0·84–1·36), but 
overall survival outcomes are awaited. The two other 
trials continue to recruit. In the AIO trial,20 patients are 
randomly allocated to one of three arms (bevacizumab 
plus ﬂ uoropyrimidine, bevacizumab alone, or no 
treatment after 24 weeks of induction oxaliplatin 
ﬂ uoropyrimidine and bevacizumab) and complete 
accrual is due in 2013. In the CAIRO 3 study,21 patients 
are randomly assigned to bevacizumab plus capecitabine 
or no treatment after 18 weeks of induction oxaliplatin, 
capecitabine, and bevacizumab.
EGFR-targeted monoclonal antibodies (cetuximab 
and panitumumab) have also been recently licensed in 
the ﬁ rst-line advanced colorectal cancer setting and 
cetuximab has been explored in an intermittent strategy 
in the Nordic VII22 and COIN-B trials.23 NORDIC VII 
demonstrated median overall survival of 20·4, 19·7, and 
20·3 months in the continuous chemotherapy alone, 
continuous chemotherapy plus cetuximab, and inter-
mittent chemotherapy plus continuous cetuximab 
arms, respectively, which were not statistically 
diﬀ erent.22 Preliminary results from the COIN-B trial 
are expected during 2011. Consequently, our ﬁ ndings 
should be interpreted cautiously for health-care 
environments in which bevacizumab, cetuximab, and 
panitumumab are widely available. However, our 
message that omission of chemotherapy for long 
periods in selected patients without overall survival 
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deﬁ cit could be even more relevant in such contexts. 
Potential beneﬁ ts from the continuation of such 
targeted agents with or without the addition of a 
ﬂ uoropyrimidine, when oxaliplatin is temporarily 
discontinued, have yet to be shown in terms of 
progression-free or strategy-failure-free survival or 
more importantly in terms of overall survival in any 
completed randomised controlled trials; such data are 
eagerly awaited.
Standard UK practice is to image patients at 12-week 
intervals. International trials, especially commercially 
sponsored studies evaluating the eﬀ ects of novel agents, 
now often use assessments every 6–8 weeks. Although 
COIN only required imaging every 12 weeks, clinical 
assessment was done every 6 weeks, during which 
clinical or biochemical progression would have been 
identiﬁ ed. During treatment breaks, patients in arm C 
attended hospital as outpatients or day cases on an 
average of two occasions every 12–24 weeks, whereas 
those in arm A would have been seen on at least eight 
occasions and possibly 12 depending on the chemotherapy 
regimen. This more frequent clinical review could have 
led to earlier identiﬁ cation of disease progression.
The secondary and subgroup analyses of the trial are 
intended to oﬀ er some guidance to practising clinicians, 
patients, and patient advocates. Against the trend to 
marginally reduced survival with intermittent chemo-
therapy is set reduced time on chemotherapy (on 
average 2·3 months less) and less frequent hospital 
attendances. There is also evidence of reduced 
cumulative toxicities of neuropathy and hand–foot 
syndrome. The overall eﬀ ect on quality of life with time 
oﬀ  treatment in arm C, as assessed at the speciﬁ c 
timepoints of 12 and 24 weeks, suggest an improvement 
in fatigue, nausea and vomiting, anorexia or loss of 
appetite, constipation, diarrhoea, dry or sore mouth, 
and diﬃ  culty handling objects. However, pain seems to 
be slightly but consistently more frequent in those 
receiving the intermittent strategy, which could be 
accounted for by the increased likelihood of tumour 
progression or activity during a chemotherapy-free 
interval. By contrast, emotional functioning appeared 
worse in the intermittent group at the end of the ﬁ rst 
12-week treatment period when all patients had received 
equivalent therapy. This result might reﬂ ect anxiety 
induced by the idea of treatment being stopped 
temporarily. Yet this ﬁ nding disappears at 24 weeks, 
when those on continuous therapy may be uncertain 
about continuing eﬀ ectiveness or tolerability of 
ongoing treatment.
In advanced colorectal cancer, for patients treated with 
palliative intent, as in most other malignancies, time oﬀ  
chemotherapy remains a treatment option. This study 
has shown and quantiﬁ ed the beneﬁ ts of a chemotherapy-
free interval in terms of reduced time on chemotherapy, 
reduced cumulative toxic eﬀ ects, and improved quality of 
life after an initial 12-week period of induction 
chemotherapy. In the whole population, there was a 
small reduction in overall survival with intermittent 
compared with continuous chemotherapy, exceeding our 
predeﬁ ned non-inferiority bound. However, the 
identiﬁ cation of raised platelet count as a potential 
biomarker separating patient subsets who do better from 
those who do not is very important. Thrombocytosis 
could identify a patient subgroup in whom cytokine 
activation is driving a more aggressive disease course, 
but which is sensitive to therapeutic intervention. By 
contrast, the three-quarters of patients in COIN with 
normal platelet counts at randomisa tion suﬀ ered no loss 
in overall survival and could reap potentially important 
beneﬁ ts of chemotherapy- free intervals.
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Panel: Research in context
Systematic review
Conventional palliative chemotherapy for treatment of advanced colorectal cancer is 
given continuously until progressive disease or cumulative toxic eﬀ ects occur, or the 
patient chooses to discontinue. In a previous Medical Research Council study, CR06B,5 
a shortened course of chemotherapy with reuse of the same treatment on progression 
showed an improvement in quality of life with no loss of survival. Similar ﬁ ndings have 
been reported in other cancer types, generally showing that short-course treatment is 
as eﬀ ective as long-course. One consistent ﬁ nding is that patients receiving 
short-course therapy can have a reduced time to disease progression, but several 
investigators have reported that at the time of progression patients can be successfully 
rechallenged with the same regimen. Searches of Medline and Cancerlit for 
publications and PDQ (Physicians Data Query) and the UKCCCR trial register for any 
additional open or closed trials in advanced colorectal cancer found no trials comparing 
these approaches when this trial was started.
Interpretation
Survival in COIN is shorter than for many international trials in advanced colorectal 
cancer, which probably reﬂ ects a more advanced stage of disease at presentation in the 
UK. Additionally, the lack of routine availability of biological agents in the UK National 
Health Service might contribute to shortened survival and therefore restrict direct 
application of the COIN data in the most resource-rich health-care settings. The ﬁ nding 
that intermittent chemotherapy is inferior in patients with raised platelet counts 
is novel and needs conﬁ rmation, but supports the conventional practice of continuous 
chemotherapy for this cohort. Conversely, for most patients with normal platelet 
counts at baseline, this study suggests that chemotherapy-free intervals are associated 
with improved quality of life and no loss of overall survival and is therefore an option 
that clinicians should discuss with such patients.
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